AREVIR 2018 Challenges for Future R-Testing Prevalence of non-M - PowerPoint PPT Presentation

AREVIR 2018 Challenges for Future R-Testing

Prevalence of non-M groups of HIV-1 in Cameroon („Congo-Basin“)

Diversity of Pol Gene (Cameroon)

AG <1% of cases by 2015 <20 cases

Phenotyping of subtype AE: Cloning Approaches 1. env (pMN-K7-LIN, pMN-env-K7) 2. vpu + env (pMN-vpuenv-K7) 3. V3 (pNL-NF-K7_V3) ? 4. ”Full” AE-Plasmid ? 14 May 2018 University of Basel 6

In vitro s sus usceptibility o of CRF0 CRF02_AG t to fo fostemsavir Francesco Saladini, Maurizio Zazzi Test of recombinant CRF02_AG strains in a phenotypic assay, preceded by phenotypic tropism determination Conclusions • The CRF02_AG is generally susceptible to TMV, however occasional variants may display reduced susceptibility. The impact of specific TMV RAMs in the context of high env genetic variability remains to be fully elucidated through phenotypic analysis and in vivo observation.

„Challenges for future Resistance-Testing” (Round Table Discussion) • 1. Are current Algorithms fit for Africa? • a. Suitable for other subtypes (C, AE) (Dirk Berzow, today) • b. are they constantly outdated? (Wagner et al, Antiviral Therapy 2016) • 2. How do we keep interpretation systems up-to-date? • a. How to update on a regular basis? (Key for African labs!) • b. How to feedback new information from clinics? • 3. Can we/do we provide regular updates for our system(s)? • a. What is needed for a relevant updating in PR, RT, IN, Fus? • b. Summary of actual changes during the past 2 years • 4. What is coming? – Open Issues • a. consider new drugs(?) • b. take (African) drug combinations into account • c. Are aspects of viral fitness relevant? • d. IS coreceptor tropism still of relevance? (U. Neogi)